I'm LongbridgeAI, I can summarize articles.Clearmind Medicine reported positive safety and tolerability results from Part A of the Phase I/II trial for CMND-100, a treatment for Alcohol Use Disorder. The dose-escalation study in healthy volunteers met its primary endpoints with no serious adverse events. These findings support the continuation of clinical development as the company prepares to advance to later stages involving patients.
- Clearmind Medicine reported positive safety results from Part A of its FDA-regulated Phase I/II trial of CMND-100 for Alcohol Use Disorder. * Results have been presented now, covering the full planned dose-escalation in healthy volunteers. * The study met its primary safety and tolerability endpoint, with no serious adverse events reported. * The outcome supports continued clinical development, with the company preparing to move into later stages that include dosing AUD patients. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300830PRIMZONEFULLFEED9800933) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)